Access Vascular – Open Syndicate

angelMD is pleased to announce that we are opening a syndicate to raise capital for Access Vascular. After reading the article below by Arun Jagannathan, MD, please click on this link to be included in exclusive communications.


The backbone of non-emergent central venous access, the ubiquitous PICC line (peripherally inserted central catheter) has become an integral patient care tool since its advent in the 1970s. In comparison to other central venous access options such as tunneled chest catheters and ports, the PICC line can be placed relatively inexpensively by an intravenous access nurse with less patient discomfort and lower risk of certain immediate complications such as pneumothorax.

Benefits vs. Complications

However, balancing these benefits are significant potential complications arising from the placement of a long catheter into a small caliber peripheral vein with multi-week indwell time. These complications include thrombosis, commonly of the peripheral vein but not infrequently of the deep central veins (deep vein thrombosis or DVT), sometimes even resulting in clinically significant pulmonary embolism (PE). Resulting catheter dysfunction typically requires secondary interventions to maintain access such as thrombolytic therapy administration or device exchange. Catheter related bloodstream infection is another potential complication which significantly increases morbidity, hospital stay and overall cost of care. These adverse events are considered avoidable and therefore not reimbursed by payors.

As a vascular and interventional radiologist, the clinical sequelae of PICC line dysfunction are well known to me, as it is my service that is tasked with fixing the problems that arise. While a majority of these lines are placed bedside, the number of difficult placements that require MD intervention is increasing at a rapid rate. Contributing to this change are a combination of factors including an older and sicker patient population who have had a multitude of venipunctures and line placements in the past leaving the venous pathways strictured or obstructed with fibrosis. Also, a greater number of patients are living longer with malignancies and other hypercoagulable states and often present with device related acute DVT/PE, requiring systemic anticoagulation and sometimes catheter directed thrombolytic therapy.

Past improvements in device design, such as antithrombotic coatings and additives, are inelegant solutions that merely mask the underlying problem caused by a thrombogenic intravenous foreign body, and, as a result, have only marginally mitigated the complications.

A Better PICC

Access Vascular has developed an advanced bulk hydrophilic biomaterial that is strong, flexible and biocompatible. The material has a high-water content and a neutral surface charge, yet is strong and load-bearing. These features make it the ideal material from which to craft long-term implantable vascular access devices in order to markedly reduce thrombosis, and in turn, almost completely eliminate complications and adverse events seen with current devices. The proprietary biomaterial is not recognized by the body as a foreign material and therefore does not trigger the body’s thrombotic response. Without adherent blood products on the catheter to act as a nidus for infection as well as the inability for microbial biofilm to grow across the hydrophilic surface, the device has the potential to significantly lower infectious complication rates without relying on antimicrobial coatings or additives.

In benchtop biocompatibility studies and short preclinical studies the biomaterial has proven to be antithrombogenic. It has shown up to a 98% reduction in thrombus accumulation in comparison to controls. The company is now conducting longer-term preclinical studies, up to and greater than 30 days of indwell time. The testing thus far has demonstrated the potential for superior clinical outcomes and lower healthcare costs compared with existing technologies.

Access Vascular expects to submit a 510K application to the FDA mid-year, with anticipated commercialization to launch as early as Q1 2018. The company recently moved into a state of the art facility and lab, where they will eventually manufacture the devices.

Acess Vascular HydropPICC vs. standard PICC

The HydroPICC is predicted to decrease morbidity, shorten hospital stays, advance treatment and improve the patient experience as well as reduce costs. While the HydroPICC will be the company’s first offering, they are in early stage development of hemodialysis access as well as implantable port devices. The aggregate venous access market is ripe for innovation as the current market leading products are less than ideal in their rate of thrombogenic and infectious complications. The combined market in the US is approximately $1.2B annually, and $3.5B worldwide.


angelMD is pleased to announce that we are opening a syndicate to raise capital for Access Vascular. If you are considering joining this exciting angelMD syndicate, please click on this link to be included in exclusive communications.

Continue reading

angelMD’s CEO Interviewed On NPR

This past week angelMD’s CEO, Tobin Arthur sat down with Florian Martin of NPR for an interview about angelMD. A copy of the interview is posted on Houston Public Media. angelMD has an office at the Texas Medical Center’s Innovation Institute , located in Houston. With a rapidly growing health care innovation sector and the largest medical center in the world, Houston is the ideal location for angelMD’s unique expertise in early stage healthcare investing.


Listen to learn about how angelMD is a “matchmaker for innovators in the medical sector” here.

Tobin Arthur

 

Continue reading

Forecasting Changes in Health Care

In health care, the pace of change has not been as fast as in the tech industry, but that is changing. We’re seeing a revolution toward meaningful personalization of therapies and services, new trends toward consumer-oriented care, transformational opportunities for population health and the convergence of social, mobile, analytics, cloud technologies and their mass adoption –  Lee Ann Jarousse, Senior Editor, H&HN.

 

The health care landscape is transitioning from analog to digital. New innovation springs forward almost every day, aiding the actions of health care professionals and patients alike. Even the stethoscope, which in itself has remained the same for the past century, is becoming digitized by the efforts of Eko Devices. Telehealth abounds. In fact, angelMD has moved the process of raising early stage capital for life science startups from analog to digital, allowing the entire process to be facilitated on our platform.

Consumers are attaining more and more opportunities to become knowledgeable of their own health and well being, which could very well shift much of what we do in health care from diagnosing and treating to management and prevention. This is concept is described in further detail by Lee Ann Jarousse in thoughts originally published in Hospital and Health Networks Magazine.


Today, patient consumers are taking a more prominent role in managing their health, well-being and the way they interact with health care services. At no time in history have people been so intimately linked with technology nor have they been such prolific generators of personal data.

  • Centralized to Distributed: A shift from hospital-centered care and doctor office visits to retail clinics, telemedicine and virtual visits.
  • Cap-Ex to Op-Ex: Instead of paying for a comprehensive doctor’s visit you pay only for a flu shot. As evidenced by the U.S. health care system, we’re moving from fee-for-service to fee-for-value with improved outcomes.
  • Static to Connected: Wearables, mobile phones and gadgets are recording ever movement. These troves of data can be leveraged with “algos” and a variety of analytics to pivot care to become smarter and more real time

Health care is shifting from diagnosing and treating to more active managing and preventing. Organizations are rethinking care models, channels and structures to design for life care. It used to be about sickness but, now and into the future, care will increasingly focus on one’s life and health span. As profit pools shift, what will matter is managing health span versus just life span.

A wave of new, digital companies are delivering convenient, seamless and personalized experiences focused on advanced 360-degree support, with an emphasis on social determinants and community-based health. These holistic approaches connect hospital to home through primary care, retail and telehealth.

In a community, population health strives to improve the social determinants that contribute to health span. An emphasis on the broader determinants of health, for example, — education, nutritional access, safety — ultimately benefit both the individual and the population in which that individual resides. The deluge of data is enabling businesses of all sizes to make more informed decisions and build solutions through real-time insights. Health care is soon to follow as the digitization of the field has been occurring over the last decade. The use of data and evidence-based protocols to predict and prevent disease and deliver health care in the most precise manner will represent a positive, disruptive use case for health care. Great advancement in imaging analytics, as well as the use of information technology and technology to improve productivity, will also be part of the industrialization of health care.


Featured image credit: Ted Eytan

Continue reading

Follow Companies on angelMD

Have you tried hitting the “follow” button on the angelMD website yet? It’s a function that allows you to receive updates whenever a startup you are interested in is doing something new or exciting.

It looks like this:

Selecting this button gives you unprecedented exposure to our vast network of startups. With this very simple yet powerful tool, you will have easy access to every major update on our network by companies that interest you. Updates are delivered to you via weekly emails from angelMD, which detail only the startups you have elected to follow.

In this way, the potentially thousands of occurrences happening on the angelMD network are packaged entirely to your customized interests, allowing you to stay up to date on only the information most pertinent to you. We encourage you to browse startups on angelMD and try it out!

 

Continue reading

angelMD: Solving Healthcare’s Biggest Challenges

“Investing in life science startups offers a potential for great financial returns, with the hope of solving some of healthcare’s biggest challenges.” -Richard Wohns

There’s a certain finesse to this statement that speaks to the principles of angelMD. We believe healthcare professionals should invest in what they know best. This creates smart investment opportunities for our physician members, and allows them to offer their expert knowledge for startups to leverage. But when considering the return on investment for operating with angelMD, the social benefit that stems from the success of life science startups can not be understated.

The companies on the angelMD website are tackling some of healthcare’s most complex and interesting challenges. Companies currently in our portfolio are addressing dire needs in healthcare, from Curtana Pharmaceuticals‘  targeted therapies for the treatment of brain cancer, to Green Sun Medical‘s transformative treatment of Scoliosis.

angelMD is at the center of innovation that could change the world, and is rapidly expanding its network of influential physicians that drive these pinnacle investments. Smart investments paired with significant social returns is at the heart of what angelMD does. Find out more about becoming a member of angelMD, and we can work together to help healthcare win.

Continue reading